NCT00268385 2026-03-19
Vorinostat and Temozolomide in Treating Patients With Malignant Gliomas
National Cancer Institute (NCI)
Phase 1 Active not recruiting
Clinical Trials
95 trialsNCT03491683 2026-03-19
INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM)
Inovio Pharmaceuticals
Phase 1/2 Active not recruiting
NCT03919071 2026-03-19
Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade Glioma
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT04573140 2026-03-19
PNOC020
University of Florida
Phase 1 Active not recruiting
NCT07225621 2026-03-19
Adjuvant Temozolomide ± 5-Aminolevulinic Acid + Low Intensity Diffuse Ultrasound Sonodynamic Therapy System for Newly Diagnosed Glioblastoma
Alpheus Medical, Inc.
Phase 2 Recruiting
NCT07326566 2026-03-19
Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
Black Diamond Therapeutics, Inc.
Phase 2 Recruiting
NCT07422363 2026-03-19
Testing the Combination of Anti-cancer Drugs Actimab-A and Cemiplimab (REGN2810) to Improve Outcomes for Patients With Recurrent Glioblastoma
National Cancer Institute (NCI)
Phase 1 Not yet recruiting
NCT02152982 2026-03-18
Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
National Cancer Institute (NCI)
Phase 2/3 Active not recruiting
NCT02375841 2026-03-18
Coping With Glioblastoma: A Study of Communication Between Physicians, Patients, and Caregivers
Memorial Sloan Kettering Cancer Center
Active not recruiting
NCT03478462 2026-03-18
CLOVER-2
Cellectar Biosciences, Inc.
Phase 1 Active not recruiting
NCT03663725 2026-03-18
StrateGlio
Centre Oscar Lambret
Phase 3 Recruiting
NCT04145115 2026-03-18
A Study Testing the Effect of Immunotherapy (Ipilimumab and Nivolumab) in Patients With Recurrent Glioma With Elevated Mutational Burden
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT04678648 2026-03-18
A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies
RasCal Therapeutics, Inc.
Phase 1 Recruiting
NCT04817254 2026-03-18
Association of Peripheral Blood Immunologic Response to Therapeutic Response to Adjuvant Treatment With Immune Checkpoint Inhibition (ICI) in Patients With Newly Diagnosed Glioblastoma or Gliosarcoma
National Institutes of Health Clinical Center (CC)
Phase 2 Active not recruiting
NCT05432804 2026-03-18
Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment
National Cancer Institute (NCI)
Phase 1/2 Suspended
NCT06325683 2026-03-18
Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT06860594 2026-03-18
Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma
National Cancer Institute (NCI)
Phase 1 Recruiting
NCT07416188 2026-03-18
Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma
National Institutes of Health Clinical Center (CC)
Phase 1/2 Not yet recruiting
NCT07480941 2026-03-18
DUAL-CAR-NK-GB
Beijing Biotech
Phase 1 Recruiting
NCT04732065 2026-03-17
PNOC023
University of California, San Francisco
Phase 1 Recruiting
NCT06161519 2026-03-17
PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN Amplifications
National Institutes of Health Clinical Center (CC)
Phase 1/2 Recruiting
NCT06344130 2026-03-17
Hypofractionation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma
National Institutes of Health Clinical Center (CC)
Phase 1 Recruiting
NCT06926075 2026-03-17
ADVICE
Filamon LTD
Phase 1/2 Recruiting
NCT06934889 2026-03-17
Study of ABBV-637 or ABBV-155 With ERAS-801 for People With Glioblastoma
Memorial Sloan Kettering Cancer Center
Phase 1 Recruiting
NCT07476794 2026-03-17
TEMPO
Sunnybrook Health Sciences Centre
Phase 2 Recruiting
NCT05109728 2026-03-16
A Dose Finding Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination With Standard of Care and in Recurrent Glioblastoma as a Single Agent.
Novartis
Phase 1 Active not recruiting
NCT05753007 2026-03-16
A Clinical Trial of a Hemp-Derived, High Cannabidiol Product for Anxiety in Glioblastoma Patients
Mclean Hospital
Phase 2 Terminated
NCT06186401 2026-03-16
Anti-EGFRvIII synNotch Receptor Induced Anti-EphA2/IL-13Ralpha2 CAR (E-SYNC) T Cells
University of California, San Francisco
Phase 1 Recruiting
NCT07472387 2026-03-16
Andro-iGlio
Assistance Publique - Hôpitaux de Paris
Phase NA Not yet recruiting
NCT03475186 2026-03-13
Testing Ramipril to Prevent Memory Loss in People With Glioblastoma
Wake Forest University Health Sciences
Phase 2 Completed
NCT03749187 2026-03-13
PNOC017
University of California, San Francisco
Phase 1 Active not recruiting
NCT06556563 2026-03-13
EF-41
NovoCure Ltd.
Phase 3 Recruiting
NCT06946680 2026-03-13
IMPACT
University of Florida
Phase 1 Active not recruiting
NCT02287428 2026-03-12
Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM
Dana-Farber Cancer Institute
Phase 1 Recruiting
NCT06333899 2026-03-12
Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion
Nationwide Children's Hospital
Phase EARLY_PHASE1 Recruiting
NCT07100730 2026-03-12
IPAX BrIGHT
Telix Pharmaceuticals (Innovations) Pty Limited
Phase 3 Recruiting
NCT07297212 2026-03-12
A Clinical Trial Testing the Safety of the Investigational Drug Pumitamig (BNT327) and How Well it Works in Patients With Recurrent Glioblastoma
BioNTech SE
Phase 2 Recruiting
NCT04044937 2026-03-11
UC-GlioFET
University of California, San Francisco
Phase 2 Completed
NCT05086497 2026-03-11
WBSI Guided Personalized Delivery of TTFields
Abramson Cancer Center at Penn Medicine
Phase NA Recruiting
NCT05743595 2026-03-11
Neoantigen-based Personalized DNA Vaccine With Retifanlimab PD-1 Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma
Washington University School of Medicine
Phase 1 Active not recruiting
NCT07464925 2026-03-11
A Phase 1 Safety and Dose Finding Study of GLIX1 in Adults With Recurrent or Progressive High-grade Glioma
Tetragon Biosciences Ltd
Phase 1 Not yet recruiting
NCT04716699 2026-03-10
Systemic and Local Levels of Lidocaine During Surgery for the Removal of Glioblastoma
University of California, Davis
Phase 1 Completed
NCT04752280 2026-03-10
GRIPS
University Hospital Heidelberg
Phase NA Recruiting
NCT07462507 2026-03-10
Inflammation in Primary and Secondary Malignancies of the Central Nervous System Using [C-11]-CS1P1
Washington University School of Medicine
Phase 2 Not yet recruiting
NCT05076513 2026-03-09
Trial of Niraparib in Participants With Newly-diagnosed Glioblastoma and Recurrent Glioma
St. Joseph's Hospital and Medical Center, Phoenix
Phase EARLY_PHASE1 Active not recruiting
NCT05182905 2026-03-09
AZD1390 in Recurrent and Newly Diagnosed WHO Grade 4 Glioma Patients
St. Joseph's Hospital and Medical Center, Phoenix
Phase EARLY_PHASE1 Active not recruiting
NCT05353530 2026-03-09
IMPACT
University of Florida
Phase 1 Active not recruiting
NCT06389591 2026-03-09
RNA-Lipid Particle (RNA-LP) Vaccines for Recurrent Adult Glioblastoma (GBM)
University of Florida
Phase 1 Active not recruiting
NCT07459101 2026-03-09
UNITED-4
Sunnybrook Health Sciences Centre
Phase NA Recruiting
NCT04391595 2026-03-06
LY3214996 Plus Abemaciclib in Recurrent Glioblastoma Patients
St. Joseph's Hospital and Medical Center, Phoenix
Phase EARLY_PHASE1 Completed